Search

everythinglearnresearchcommunity

for

Search:↓

A user is considering switching to a topical treatment containing finasteride, minoxidil, and tretinoin, instead of their current regimen of oral finasteride and oral minoxidil. They are unsure whether to try the new topical or continue with their current treatment.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

The user has been using oral finasteride and topical minoxidil for three years, seeing some regrowth initially but mostly maintenance afterward. Suggestions for further improvement include trying dutasteride, RU58841, or a hair transplant.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

The user initially started finasteride at 5mg unknowingly, then experimented with various minoxidil formulations, leading to inconsistent results and hair loss. They resumed treatment with topical finasteride and minoxidil, seeing some regrowth, and are now using a more structured regimen while considering a hair transplant.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

A 26-year-old shared their 3-month hair regrowth progress using finasteride, oral and topical minoxidil, a mane solution with various oils and extracts, and microneedling. They plan to add curcumin topically and are open to suggestions for their aggressive treatment protocol.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

The user switched from finasteride to dutasteride for hair loss treatment, also using topical minoxidil, micro needling, keto shampoo, and PRP sessions. They've seen improvements, with reduced hair shedding and new hair growth, especially at the hairline.

The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

A user shared their 3-month progress using oral finasteride, topical minoxidil, and dermarolling for hair loss. Other users commented on the impressive results and asked questions about the treatments.

The user experienced noticeable hair regrowth in three months using finasteride, minoxidil, and weekly dermastamping, while managing scalp inflammation with clobetasol. The user also uses a sea salt shampoo and rosemary conditioner to help maintain scalp health.

A user experienced significant hair regrowth after 3 months of using 2.5mg oral minoxidil but also noticed unwanted body hair growth. Suggestions included switching to dutasteride or adding finasteride to address hair loss more effectively.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

After 3 months of using oral minoxidil and finasteride, the user experienced thicker hair and filled-in thinning areas, with no major side effects except an initial shedding phase. The treatments were prescribed online, and the user noticed results after 2.5 months.

The user experienced side effects from various hair loss treatments, including RU58841, finasteride, and dutasteride. They are uncertain about what treatment to try next.

GHK-Cu and Acetyl Tetrapeptide-3 are ineffective for hair regrowth according to user experiences. Effective treatments mentioned are finasteride, dutasteride, and minoxidil.

A user shared their positive experience with hair regrowth after 3 months using finasteride, minoxidil, and vitamins such as biotin, B5, B6, and C. They took 1.1 mg of oral finasteride, experienced a shedding period initially, and emphasized the importance of consistency.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The conversation is about a person's 3-month hair loss treatment using Minoxidil with crushed Finasteride tablets and weekly dermarolling. They shared their progress pictures.

A 24-year-old shared three months of progress using dutasteride, minoxidil, and biotin for hair loss. The post includes progress pictures and discusses the effectiveness of these treatments.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.